To transect or not to transect the bulbar urethra? That's the question. ➡️Level Ib evidence coming up! 🔹International collaboration 🙏 🔹So far, 81/100 patients randomized 🌎-wide 🔹Published protocol 👇 https://t.co/1d7Als7tA0

Most expert GU oncologists were supportive of discussing de-escalation of systemic ADT+ARPI in mHSPC #ProstateCancer after achieving PSA<0.2 ng/ml at 2024 @APCCC_Lugano conference 👉 Dr @Silke_Gillessen discusses mHSPC de-intensification trials @13th EOC👇@OncoAlert @PCF_Science

Lots of ❓s in defining benefits of “#oligomet” or “#MDT” therapy in #ProstateCancer ❓ADT+/-ARPI? How long? ❓PFS vs Eugonadal PFS? ❓how many mets? Where? 🔑❓what imaging 🩻❓ #PSMA mets🚫🟰CT/Bone scan mets https://t.co/LFMdSkoVln Std of Care? Or just something we can do?

Very important findings — congratulations, Nik and the team!👉New data at @AACR @theNCI @EORTC 2025 show that membranous NECTIN-4 expression in UC #bladdercancer is heterogeneous, detected in only 113/176 EV-naïve samples (~1/3 negative). This reinforces that NECTIN-4 is not

1/ 🚨 Pleased to share that our latest manuscript is out now in @EUplatinum! Baseline and on-treatment #ctDNA biomarkers in men with advanced #ProstateCancer treated with #LuPSMA. https://t.co/koAm8SgnK9 Thanks to @LouiseKostos Heidi Fettke @PeterMacCC

Fantastic talk by @DrPaulNguyen #ESMO25 👉result of ph3 Enzarad trial👉Addition of ENZA to ADT + radiation did not improve MFS in all high risk localized, the primary endpoint. However, node+ on CT/MRI pts derived benefit, like Stampede trial @OncoAlert @urotoday @PCF_Science

⚡️ Phase 3 POTOMAC: Adding durvalumab to BCG (induction+maintenance) in BCG-naive high-risk NMIBC cut recurrence/death by 32% vs BCG alone (HR 0.68) with ~61-mo follow-up. Higher grade ≥3 AEs (21% vs 4%). Potential practice shift pending guidelines. #BladderCancer

A standing ovation moment at #ESMO25 In front of more than 9,000 cancer specialists and researchers, the Phase 3 RC48-C016 trial redefined the outlook for HER2-expressing urothelial cancer: Disitamab vedotin + Toripalimab nearly doubled overall survival over chemotherapy —

🚨Just in @NatureMedicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 https://t.co/BYx1L9i7GC @PCFnews @OncoAlert @urotoday

📘 The EAU Urological Infection Panel has introduced a new UTI classification: - Localized UTI: no systemic symptoms - Systemic UTI: systemic signs ± urinary symptoms Clarity in diagnosis = better care. #Urology #Infection #UTI https://t.co/0RhgcZhCkH

Would surgery add survival benefit to the systemic treatment in patients with oligometastatic prostate cancer ? A new data highlights this; 👉Adding radical prostatectomy to best systemic therapy cut 5-yr cancer-specific mortality from 23% to 13% (HR 0.39, p=0.045). Early

My mentor and beloved friend @KoenraadvanRen1 sharing knowledge, skills and future perspectives in sexual medicine and penile implant surgery 👌🏻@OsmonovDr @drserefoglu @Uroweb @essm_tweets @JessaZiekenhuis during #ESGURS #ESAU25 @SkrodzkaM @donwglee

🔥 LUNAR trial: In oligometastatic hormone-sensitive #ProstateCancer, adding 2 cycles of 177Lu-PSMA 💥 ☢️ before SBRT ⬆️ doubled PFS (18 vs 7 mo, HR 0.32, p<0.001) with minimal added adverse events. 🚀 PSMA-RLT + SBRT = new frontier #ASTRO25 #RadOnc #NuclearMedicine @ASTRO_org

💥Phase III BART trial (n=153) in locally advanced #BladderCancer after cystectomy + chemo: 🔹 RT (n=77) vs Obs (n=76) 🔹2-yr locoregional recurrence: 8% RT vs 26% Obs (p=0.006) 🔹OS trend ↑RT (68% vs 57%), not sig 🔹No ↑ severe late adverse events 👉Adjuvant RT ↑ control &

Our new meta-analysis has just been published! 🎉 PARP inhibitors may be linked to increased VTE risk overall ↗️ (2.4% vs 1.6%; OR 1.37; 95% CI 1.00–1.88). Signals vary by cancer type 🧬 Highlights: • Prostate cancer: higher VTE risk (OR 1.98; P=0.03) 📌 • Pancreatic cancer:

💫🌟🚨 NEW in @NEJM Adjuvant Pembrolizumab vs Observation in MIUC 📘 #Alliance A031501 / #AMBASSADOR Trial 🧪 N=702 | Median follow-up: 44.8 months 🔗 https://t.co/fJbu7dPAlq 🎓 @apolo_andrea, @PGrivasMDPhD, @sonpavde, @bergsa83, @WilliamKimMD, @BradMcG04, @SuzanneColeMD,

🔥 Hot off the press! Do patients need antibiotics before shockwave lithotripsy (SWL)? Guidelines disagree. Evidence has been weak. Our landmark #APPEALtrial - by far the largest and most robust blinded trial to date - is here. 🧵 1/8 #EBM #urology #UTI #prophylaxis #AMR

📣In high-risk nonmetastatic upper tract urothelial cancer, neoadjuvant gemcitabine + split-dose cisplatin yields durable benefit. 👉At 7 yrs, responders had DFS 78% vs 31%, CSS 90% vs 56%, OS 87% vs 48%. Supports NAC as standard for high-risk UTUC. @OncoAlert @arihakimi

Patient satisfaction, quality of life, and catheter-related complications in long-term urinary catheter users: A nationwide survey. #AuthorCommentary 📊 Nationwide survey of 3,320 long-term #urinarycatheter users shows: ✔️ Clean Intermittent Catheterization (CIC) → higher

Not all UTIs need immediate antibiotics. EAU survey: only 8% knew that ~30–40% of cases may resolve without immediate antibiotics. Guidelines support careful prescribing & shared decision-making. #UrologyWeek may be ending, but awareness must continue from clinic to community.

🆕 in European Urology (Editor’s Choice) Systematic review of MRI in prostate cancer screening: ✔ Improves detection of clinically significant PCa ✔ Cuts unnecessary biopsies ✔ Best results with 2nd-stage MRI after PSA Full text 👉 https://t.co/6fmdqOC84m #ProstateCancer #MRI